Novel systemic therapy to improve clinical outcome in small cell lung cancer

改善小细胞肺癌临床结果的新型全身疗法

• 批准号: 8531195
• 负责人: Taofeek K Owonikoko
• 金额: $ 16.31万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-26 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8531195
• 关键词: Address; Antineoplastic Agents; Applications Grants; Arsenic Trioxide; Award; Biological; Biology; Cancer Biology; Cancer Center; Cancer Patient; Chest; Cisplatin; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Design; Collaborations; Conduct Clinical Trials; Cytotoxic agent; DNA Damage; DNA Repair; Development; Development Plans; Diagnosis; Differentiation Inducer; Disease; Doctor of Philosophy; Eastern Cooperative Oncology Group; Educational Curriculum; Enrollment; Ensure; Environment; Ethics; Etoposide; Excision; Extensive Stage; Fine needle aspiration biopsy; Funding; Future; Goals; Growth; Hematology; Home environment; Immunodeficient Mouse; In Vitro; Industry; Institutes; Institution; Knowledge; Laboratories; Lead; Leadership; Learning; Malignant Neoplasms; Malignant neoplasm of lung; Manufacturer Name; Master of Science; Medical Oncology; Mentors; Mentorship; Multicenter Trials; NCI-Designated Cancer Center; Neoplasm Transplantation; Newly Diagnosed; Newly Diagnosed Disease; Operative Surgical Procedures; Outcome; Participant; Patients; Pharmaceutical Preparations; Phase II Clinical Trials; Placebos; Preparation; Progression-Free Survivals; Randomized; Recurrent disease; Refractory; Regimen; Regulation; Relapse; Research; Research Design; Research Personnel; Resistance; Resources; Role; Salvage Therapy; Sampling; Scientist; Secure; Source; Staging; Structure; Survival Rate; Systemic Therapy; Techniques; Testing; The Sun; Therapeutic; Therapeutic Agents; Tissue Sample; Toxic effect; Training; Training Programs; Translating; Translational Research; Translations; Tumor Bank; Tumor Biology; Universities; Vision; Work; Xenograft procedure; base; cancer therapy; career; career development; chemotherapy; clinical care; clinical efficacy; cytotoxic; design; didactic education; disorder control; drug testing; effective therapy; experience; human FRAP1 protein; improved; inhibitor/antagonist; interest; lung small cell carcinoma; mortality; novel; novel therapeutic intervention; patient oriented research; patient population; pre-clinical; preclinical evaluation; professor; programs; repair enzyme; research and development; response; tumor

DESCRIPTION (provided by applicant): This candidate is an Assistant Professor in Hematology and Medical Oncology at Emory University. His long- term career goal is to become established as an independent translational researcher with recognized superior expertise in clinical care of lung cancer patients, conduct of clinical trials leading to the development of new treatment options for small cell lung cancer (SCLC) and in the preclinical evaluation of novel compounds likely to develop into effective therapy for SCLC. The candidate is interested in advancing the care and clinical outcome of SCLC patients by investigating new treatment options and developing effective strategies to improve on the efficacy of currently available therapies. The candidate has proposed a career development plan that includes a multi-faceted training and mentoring program designed to provide an intense, patient- oriented research experience. These goals will be achieved through his lead role in the design and conduct of two clinical trials enrolling SCLC patients. The first trial is a single institution study designed by he candidate that will evaluate the clinical efficacy of arsenic trioxide in relapsed disease. If successful, this clinical trial will introduce a novel therapy into the treatment options for the refractory patient population. The second clinical trial is a direct translation of the candidate's preclinical laboratory work designed to evaluate whether the addition of ABT-888, an orally administered PARP inhibitor, will enhance the efficacy of standard chemotherapy agents without increased toxicity in newly diagnosed SCLC patients. This study is planned as a multi-institution clinical trial to be conducted through the established cooperative group mechanism of ECOG. Additionally, in preparation for a long term career as a translational scientist, the candidate proposes the establishment of a SCLC tumor bank by xenogeneic transplantation of tumor samples to immunodeficient mice during this period of mentored training. This unique resource will support ongoing and future preclinical evaluation of new anticancer agents and facilitate the understanding of the unique biology of SCLC. Simultaneous with this intense practical experience in patient-oriented research, the candidate will participate in a formal well-structured didactic curriculum leading to the award of a Masters of Science in Clinical Research from his home institution, Emory University. This course of study is a rigorous multi-year curriculum designed to provide participants with a deep knowledge and comprehensive understanding of the ethics, design, conduct and regulation of patient-oriented research. This overall training and practical experience will occur under the lead mentorship of Dr. Fadlo Khuri, an accomplished translational researcher with track record of successfully mentoring all cadres of clinicians and basic scientists. He will be assisted by co-mentors with complementary expertise including Suresh Ramalingam, MD, an internationally renowned clinical investigator with superb expertise in lung cancer; Shi-Yong Sun, PhD, a highly experienced basic scientist and a world leader in mTOR biology; and Mourad Tighiouart, PhD, a biostatistician with strong interest in design of clinical trials to evaluate promising anticancer agents. This training program will occur at Emory University and the Winship Cancer Institute of Emory University which provide an ideal environment for learning, training and practical exposure in patient-oriented research and a unique opportunity for collaboration between basic scientists and clinical investigators. The Winship Cancer Institute is an NCI-designated cancer center which ensures the proper conduct of investigator-initiated single center studies as well as participation in large cooperative group clinical trials as proposed in this application. It is expected that at the end of this mentoring period, the candidate will be adequately prepared to pursue an independent research career focused on SCLC and will be highly competitive for research funding and academic leadership roles.

描述（由申请人提供）：该候选人是埃默里大学血液学和肿瘤医学助理教授。他的长期职业目标是成为一名独立的转化研究人员，在肺癌患者的临床护理方面具有公认的卓越专业知识，进行临床试验，从而开发新的治疗方法